Search research articles
Contact Us
Filters
Showing results (161-170 of 173) with videos related to
Page
of 18
Sort By:
Molecular Pharmacology
|
March 5, 2022
VU6036720: The First Potent and Selective In Vitro Inhibitor of Heteromeric Kir4.1/5.1 Inward Rectifier Potassium Channels
Samantha J McClenahan, Caitlin N Kent, Sujay V Kharade, et al.
Journal of Medicinal Chemistry
|
December 22, 2006
Design, synthesis, and biological evaluation of peptidomimetic inhibitors of factor XIa as novel anticoagulants
Jian Lin, Hongfeng Deng, Lei Jin, et al.
Molecular Pharmacology
|
July 31, 2008
Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4
Colleen M Niswender, Kari A Johnson, C David Weaver, et al.
The Journal of Biological Chemistry
|
October 4, 2012
Identification and characterization of a compound that protects cardiac tissue from human Ether-à-go-go-related gene (hERG)-related drug-induced arrhythmias
Franck Potet, Amanda N Lorinc, Sebastien Chaigne, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 18, 2012
Optimization of an ether series of mGlu5 positive allosteric modulators: molecular determinants of MPEP-site interaction crossover
Jason T Manka, Paige N Vinson, Karen J Gregory, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 12, 2011
Phase I studies of CBP501, a G2 checkpoint abrogator, as monotherapy and in combination with cisplatin in patients with advanced solid tumors
Geoffrey I Shapiro, Raoul Tibes, Michael S Gordon, et al.
Molecular Pharmacology
|
October 7, 2010
Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity
Alice L Rodriguez, Mark D Grier, Carrie K Jones, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 28, 2013
Discovery of (S,E)-3-(2-fluorophenyl)-N-(1-(3-(pyridin-3-yloxy)phenyl)ethyl)-acrylamide as a potent and efficacious KCNQ2 (Kv7.2) opener for the treatment of neuropathic pain
Yong-Jin Wu, Charles M Conway, Li-Qiang Sun, et al.
Journal of Medicinal Chemistry
|
July 11, 2003
(S)-N-[1-(3-morpholin-4-ylphenyl)ethyl]- 3-phenylacrylamide: an orally bioavailable KCNQ2 opener with significant activity in a cortical spreading depression model of migraine
Yong-Jin Wu, Christopher G Boissard, Corinne Greco, et al.
ACS Chemical Neuroscience
|
September 17, 2014
Identification of positive allosteric modulators VU0155094 (ML397) and VU0422288 (ML396) reveals new insights into the biology of metabotropic glutamate receptor 7
Nidhi Jalan-Sakrikar, Julie R Field, Rebecca Klar, et al.
Page
of 18
Search research articles
Search
Showing results (161-170 of 173) with videos related to
Sort By:
Page
of 18
Molecular Pharmacology
|
March 5, 2022
VU6036720: The First Potent and Selective In Vitro Inhibitor of Heteromeric Kir4.1/5.1 Inward Rectifier Potassium Channels
Samantha J McClenahan, Caitlin N Kent, Sujay V Kharade, et al.
Journal of Medicinal Chemistry
|
December 22, 2006
Design, synthesis, and biological evaluation of peptidomimetic inhibitors of factor XIa as novel anticoagulants
Jian Lin, Hongfeng Deng, Lei Jin, et al.
Molecular Pharmacology
|
July 31, 2008
Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4
Colleen M Niswender, Kari A Johnson, C David Weaver, et al.
The Journal of Biological Chemistry
|
October 4, 2012
Identification and characterization of a compound that protects cardiac tissue from human Ether-à-go-go-related gene (hERG)-related drug-induced arrhythmias
Franck Potet, Amanda N Lorinc, Sebastien Chaigne, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 18, 2012
Optimization of an ether series of mGlu5 positive allosteric modulators: molecular determinants of MPEP-site interaction crossover
Jason T Manka, Paige N Vinson, Karen J Gregory, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 12, 2011
Phase I studies of CBP501, a G2 checkpoint abrogator, as monotherapy and in combination with cisplatin in patients with advanced solid tumors
Geoffrey I Shapiro, Raoul Tibes, Michael S Gordon, et al.
Molecular Pharmacology
|
October 7, 2010
Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity
Alice L Rodriguez, Mark D Grier, Carrie K Jones, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 28, 2013
Discovery of (S,E)-3-(2-fluorophenyl)-N-(1-(3-(pyridin-3-yloxy)phenyl)ethyl)-acrylamide as a potent and efficacious KCNQ2 (Kv7.2) opener for the treatment of neuropathic pain
Yong-Jin Wu, Charles M Conway, Li-Qiang Sun, et al.
Journal of Medicinal Chemistry
|
July 11, 2003
(S)-N-[1-(3-morpholin-4-ylphenyl)ethyl]- 3-phenylacrylamide: an orally bioavailable KCNQ2 opener with significant activity in a cortical spreading depression model of migraine
Yong-Jin Wu, Christopher G Boissard, Corinne Greco, et al.
ACS Chemical Neuroscience
|
September 17, 2014
Identification of positive allosteric modulators VU0155094 (ML397) and VU0422288 (ML396) reveals new insights into the biology of metabotropic glutamate receptor 7
Nidhi Jalan-Sakrikar, Julie R Field, Rebecca Klar, et al.
Page
of 18